# Marc Montserrat

> Marc Montserrat is the Chief Executive Officer of DNA Script, a French-American biotech pioneering enzymatic DNA synthesis - a technology that lets labs print custom DNA on demand, in hours instead of days. A Wharton MBA and industrial engineer by training, Montserrat spent two decades building commercial operations at Ariosa Diagnostics (prenatal testing), Omniome (next-gen sequencing), and Deepcell (AI-powered single-cell analysis) before co-founding Splice Bio and ultimately landing as CEO of DNA Script in October 2024. He was drawn into life sciences after a misdiagnosis scare at 24 that convinced him life was too short to spend on work without meaning.

- **Role:** Chief Executive Officer at DNA Script
- **Organizations:** DNA Script, Splice Bio, Deepcell, Omniome, Ariosa Diagnostics, Roche Diagnostics, Siemens
- **Nationality:** Spanish
- **Education:** Master's in Industrial Engineering, Universitat Politècnica de Catalunya, MBA (with honors), University of Pennsylvania, Wharton School
- **Known for:** Appointed CEO of DNA Script in October 2024, succeeding founding CEO Thomas Ybert, Helped scale Ariosa Diagnostics from startup through its acquisition by Roche and successful integration, Built commercial operations at Omniome (later acquired by Pacific Biosciences)

## Career timeline

- **Early career** — Industrial engineer - project manager at Siemens in industrial manufacturing
- **Early career** — Project manager at a pharmaceutical company
- **2010s** — Joined Ariosa Diagnostics; helped create and scale the prenatal testing (NIPT) market
- **2016** — Ariosa Diagnostics acquired by Roche; Montserrat became International Business Leader for NIPT at Roche Diagnostics
- **2019-2021** — VP of Commercial Development at Omniome; built business development, marketing, and service teams for next-gen sequencing platform
- **2020-2022** — Chief Business Officer at Deepcell; led commercial strategy for AI-powered single-cell analysis startup
- **2022-2024** — Co-founded Splice Bio, a genetic medicine company
- **2024-10** — Appointed Chief Executive Officer of DNA Script

## Achievements

- Appointed CEO of DNA Script in October 2024, succeeding founding CEO Thomas Ybert
- Helped scale Ariosa Diagnostics from startup through its acquisition by Roche and successful integration
- Built commercial operations at Omniome (later acquired by Pacific Biosciences)
- Led business development as CBO at Deepcell, an AI-powered single-cell analysis pioneer
- Co-founded Splice Bio, a genetic medicine company focused on genetic therapies
- Under his early leadership at DNA Script, the company signed an MOU with EVA Pharma and Quantoom Biosciences to build an mRNA vaccine platform capable of 100M doses/year in Egypt
- DNA Script has cumulatively raised over $440M in equity financing and filed 150+ patent applications

## Latest updates

- **2025-02** — DNA Script signed an MOU with EVA Pharma and Quantoom Biosciences to build an mRNA vaccine production platform in Egypt capable of 100 million doses per year.
- **2024-10** — Marc Montserrat appointed CEO of DNA Script, succeeding co-founder Thomas Ybert who moved to Chief Scientific Officer.
- **2024-10** — DNA Script announced continued commercialization push with SYNTAX System benchtop enzymatic DNA synthesizer.

## Links

- Website: https://dnascript.com
- LinkedIn: http://www.linkedin.com/in/marc-montserrat-33b6334
- Twitter/X: https://twitter.com/dnascript

---

Profile page: https://yespress.io/marc-montserrat
Published by YesPress — https://yespress.io
Last updated: 2026-05-16